Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors

Дата публикации: 25-06-2026 00:00:00

This cohort study explores the long-term outcomes of patients with platinum-sensitive recurrent ovarian cancer who have exceptional response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Team finds way to reverse ovarian cancer’s chemo resistance	5	8	25-06-2026
2	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
3	Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy	0	7	18-06-2026
4	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
5	Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer	0	7	25-06-2026
6	Survival in the SONIA Trial	0	8	18-06-2026
7	Error in Open Access License	0	5	18-06-2026
8	Survival in the SONIA Trial	0	7	18-06-2026
9	Three-Body Problem at Digital Frontiers	0	5	25-06-2026
10	СМИ: почти каждая четвертая россиянка трудоспособного возраста умирает от новообразований	0	0	03-07-2019

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.